ES2074982T3 - Unidad de dosificacion transdermica de estrogeno/progestina, y estuche de control de la fertilidad que comprende dicha unidad de dosificacion. - Google Patents

Unidad de dosificacion transdermica de estrogeno/progestina, y estuche de control de la fertilidad que comprende dicha unidad de dosificacion.

Info

Publication number
ES2074982T3
ES2074982T3 ES87311508T ES87311508T ES2074982T3 ES 2074982 T3 ES2074982 T3 ES 2074982T3 ES 87311508 T ES87311508 T ES 87311508T ES 87311508 T ES87311508 T ES 87311508T ES 2074982 T3 ES2074982 T3 ES 2074982T3
Authority
ES
Spain
Prior art keywords
estrogen
progestin
dosage units
layer
fertility control
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES87311508T
Other languages
English (en)
Inventor
Yie W Chien
Te-Yen Chien
Yih-Chain Huang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Rutgers, The State University of New Jersey
Original Assignee
Rutgers, The State University of New Jersey
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rutgers, The State University of New Jersey filed Critical Rutgers, The State University of New Jersey
Application granted granted Critical
Publication of ES2074982T3 publication Critical patent/ES2074982T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
    • A61K9/7061—Polyacrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7092—Transdermal patches having multiple drug layers or reservoirs, e.g. for obtaining a specific release pattern, or for combining different drugs

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

SE HAN DESARROLLADO UNIDADS DE DOSIFICACION POR ABSORCION DE ESTROGENO/PROGESTINA TRANSDERMICAS, QUE COMPRENDEN UNA CAPA RESERVA, UNA CAPA POLIMERA CONTIGUA ES UNA CAPA ADHESIVA EN LA QUE SE DISUELVE Y/O MICRODISPERSA POR LO MENOS UNA DOSIS EFECTIVA MINIMA DE UN ESTROGENO. ADHERIDA A LA CAPA POLIMERA ESTA UNA CAPA ADHESIVA EN LA QUE SE DISUELVEN Y/O MICRODISPERSAN POR LO MENOS DOSIS MINIMAS DE PROGESTINA. ACTUALMENTE SE PREFIERE USAR ESTROGENO NATURAL, 17-ESTRADIOL, O ETINIL ESTRADIOL, O SUS COMBINACIONES Y PROGESTINA, NORETINDRONA O NORGESTIMATO O SUS COMBINACIONES. LAS UNIDADES TIENEN CAPAS POLIMERAS Y ADHESIVAS BIOLOGICAMENTE ACEPTABLES. LA CAPA ADHESIVA PUEDE TENER DISPERSO UNO O MAS AGENTES PARA MEJORAR LA PERMEABILIDAD DE LA PIEL. SE PUEDE USAR OPCIONALMENTE UNA CAPA DE SEPARACION EN LA FABRICACION DE UNIDADES DE DOSIFICACION, QUE SEPARA LAS CAPAS ADHESIVA Y POLIMERA, LO QUE PERMITE LA TRANSMISION DEL ESTROGENO DESDE LA CAPA POLIMERA DURANTE EL TRATAMIENTO. SE PROPORCIONAN UNIDADES DE DOSIFICACION QUE LIBERAN TRANSDERMICAMENTE POR LO MENOS DOSIS DIARIAS MINIMAS DE ESTROGENO Y PROGESTINA DURANTE VARIOS DIAS COMO DURANTE UNA SEMANA. LA INVENCION TAMBIEN PROPORCIONA UN PROCEDIMIENTO PARA CONTROL DE FERTILIDAD Y TERAPIA DE SUSTITUCION DE ESTROGENO, UTILIZANDO LAS NUEVAS UNIDADES DE DOSIFICACION. LA INVENCION TAMBIEN PROPORCIONA UN SISTEMA DE CONTROL DE FERTILIDAD UTILIZANDO LAS NUEVAS UNIDADES DE DOSIFICACION.
ES87311508T 1986-12-29 1987-12-29 Unidad de dosificacion transdermica de estrogeno/progestina, y estuche de control de la fertilidad que comprende dicha unidad de dosificacion. Expired - Lifetime ES2074982T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US94713086A 1986-12-29 1986-12-29
US13146287A 1987-12-16 1987-12-16

Publications (1)

Publication Number Publication Date
ES2074982T3 true ES2074982T3 (es) 1995-10-01

Family

ID=26829495

Family Applications (1)

Application Number Title Priority Date Filing Date
ES87311508T Expired - Lifetime ES2074982T3 (es) 1986-12-29 1987-12-29 Unidad de dosificacion transdermica de estrogeno/progestina, y estuche de control de la fertilidad que comprende dicha unidad de dosificacion.

Country Status (11)

Country Link
EP (1) EP0275716B1 (es)
CN (1) CN1021196C (es)
AT (1) ATE126068T1 (es)
AU (1) AU1242388A (es)
CA (1) CA1313623C (es)
DE (1) DE3751447T2 (es)
ES (1) ES2074982T3 (es)
GR (1) GR3018010T3 (es)
IE (1) IE69752B1 (es)
NZ (1) NZ223088A (es)
WO (1) WO1989005663A1 (es)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5145682A (en) * 1986-05-30 1992-09-08 Rutgers, The State University Of New Jersey Transdermal absorption dosage unit for postmenopausal syndrome treatment and process for administration
US5560922A (en) * 1986-05-30 1996-10-01 Rutgers, The State University Of New Jersey Transdermal absorption dosage unit using a polyacrylate adhesive polymer and process
US5023084A (en) * 1986-12-29 1991-06-11 Rutgers, The State University Of New Jersey Transdermal estrogen/progestin dosage unit, system and process
CH674618A5 (es) * 1987-04-02 1990-06-29 Ciba Geigy Ag
WO1990004397A1 (de) 1988-10-27 1990-05-03 Schering Aktiengesellschaft Berlin Und Bergkamen Mittel zur transdermalen applikation enthaltend gestoden
PH30747A (en) * 1989-03-10 1997-10-17 Endorech Inc Combination therapy for the treatment of estrogen sensitive disease.
US5059426A (en) * 1989-03-22 1991-10-22 Cygnus Therapeutic Systems Skin permeation enhancer compositions, and methods and transdermal systems associated therewith
US4973468A (en) * 1989-03-22 1990-11-27 Cygnus Research Corporation Skin permeation enhancer compositions
US5053227A (en) * 1989-03-22 1991-10-01 Cygnus Therapeutic Systems Skin permeation enhancer compositions, and methods and transdermal systems associated therewith
US5252334A (en) * 1989-09-08 1993-10-12 Cygnus Therapeutic Systems Solid matrix system for transdermal drug delivery
DE3933460A1 (de) * 1989-10-06 1991-04-18 Lohmann Therapie Syst Lts Oestrogenhaltiges wirkstoffpflaster
JP3273430B2 (ja) * 1989-12-28 2002-04-08 日東電工株式会社 エストロゲン含有ゲル製剤
GB9021674D0 (en) * 1990-10-05 1990-11-21 Ethical Pharma Ltd Transdermal device
DE4227989A1 (de) * 1992-08-21 1994-06-09 Schering Ag Mittel zur transdermalen Applikation enthaltend 3-Keto-desogestrel
GB2273044B (en) * 1992-12-02 1997-04-09 Pacific Chem Co Ltd Medicinal patches for percutaneous administration
DE4336557C2 (de) 1993-05-06 1997-07-17 Lohmann Therapie Syst Lts Estradiolhaltiges transdermales therapeutisches System, Verfahren zu seiner Herstellung und seine Verwendung
NL9301562A (nl) * 1993-09-09 1995-04-03 Saturnus Ag Preparaat voor substitutietherapie.
DE4400770C1 (de) * 1994-01-13 1995-02-02 Lohmann Therapie Syst Lts Wirkstoffhaltiges Pflaster zur Abgabe von Estradiol mit mindestens einem Penetrationsverstärker, Verfahren zu seiner Herstellung und seine Verwendung
IL116539A (en) * 1995-01-06 2002-02-10 Noven Pharma Preparations given through the skin of unstable anti-acid drugs
US6024974A (en) * 1995-01-06 2000-02-15 Noven Pharmaceuticals, Inc. Composition and methods for transdermal delivery of acid labile drugs
DE19500662C2 (de) * 1995-01-12 2001-04-26 Lohmann Therapie Syst Lts Estradiolhaltiges Pflaster und seine Verwendung
PL181582B1 (pl) * 1995-06-07 2001-08-31 Ortho Mcneil Pharm Inc Plaster na skóre do zapobiegania owulacji u kobiety oraz plaster na skóre do przeprowadzania hormonalnej terapii substytucyjnej PL PL PL PL PL PL PL PL
DE19700913C2 (de) 1997-01-14 2001-01-04 Lohmann Therapie Syst Lts Transdermales therapeutisches System zur Abgabe von Hormonen
DE19705138A1 (de) * 1997-02-11 1998-08-13 Lohmann Therapie Syst Lts Dehnbares transdermales therapeutisches System
DE19834007C1 (de) 1998-07-29 2000-02-24 Lohmann Therapie Syst Lts Estradiolhaltiges Pflaster zur transdermalen Applikation von Hormonen und seine Verwendung
CA2267743C (en) 1999-03-30 2011-07-26 Robert F. Casper Low dose estrogen interrupted hormone replacement therapy
WO2000062753A1 (de) * 1999-04-16 2000-10-26 Jenapharm Gmbh & Co. Kg Pharmazeutische oder kosmetische zusammensetzungen zur lokalen, intradermalen applikation von hormonen
US7384650B2 (en) * 1999-11-24 2008-06-10 Agile Therapeutics, Inc. Skin permeation enhancement composition for transdermal hormone delivery system
DE10056014A1 (de) * 2000-11-11 2002-05-16 Beiersdorf Ag Mehrschichtige Trägerkonstruktion für wirkstofhaltige Pflastersyteme
DE10056012A1 (de) * 2000-11-11 2002-05-16 Beiersdorf Ag Flexible Barrierefolie für ein Trägermaterial für medizinische Zwecke
AU2003220171A1 (en) * 2002-03-11 2003-09-29 Janssen Pharmaceutica N.V. Continuous sulfatase inhibiting progestogen hormone replacement therapy
DE102011100619A1 (de) 2010-05-05 2012-01-05 Amw Gmbh Transdermales therapeutisches System (TTS) mit einem Gehalt an einem Opiod-Analgetikum
DE102011119043A1 (de) 2011-11-22 2013-05-23 Alfred E. Tiefenbacher (Gmbh & Co. Kg) Transdermales therapeutisches System (TDS) mit Rotigotin
EP2782584B1 (en) 2011-11-23 2021-06-09 TherapeuticsMD, Inc. Natural combination hormone replacement formulations and therapies
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
WO2013112947A1 (en) * 2012-01-26 2013-08-01 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
US20130338122A1 (en) 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
AR100562A1 (es) 2014-05-22 2016-10-12 Therapeuticsmd Inc Composición farmacéutica de estradiol y progesterona para terapia de reemplazo hormonal
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
KR20180126582A (ko) 2016-04-01 2018-11-27 쎄러퓨틱스엠디, 인코퍼레이티드 스테로이드 호르몬 약제학적 조성물
WO2017173044A1 (en) 2016-04-01 2017-10-05 Therapeuticsmd Inc. Steroid hormone compositions in medium chain oils
CN121617562B (zh) * 2026-02-03 2026-04-28 西安市第一医院 绝经后骨质疏松风险预测及中西医干预管理系统

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3832252A (en) * 1970-09-29 1974-08-27 T Higuchi Method of making a drug-delivery device
US3992518A (en) * 1974-10-24 1976-11-16 G. D. Searle & Co. Method for making a microsealed delivery device
US4145416A (en) * 1976-06-23 1979-03-20 Schering, A.G. Novel agents and novel methods for treatment of climacteric disturbances
JPS56133381A (en) * 1980-03-25 1981-10-19 Nippon Kayaku Co Ltd Pressure-sensitive adhesive tape or sheet containing nitroglycerin
US4336243A (en) * 1980-08-11 1982-06-22 G. D. Searle & Co. Transdermal nitroglycerin pad
US4544554A (en) * 1983-09-26 1985-10-01 Ortho Pharmaceutical Corporation Triphasic oral contraceptive
US4628051A (en) * 1983-09-26 1986-12-09 Ortho Pharmaceutical Corporation Triphasic oral contraceptive
US4624665A (en) * 1984-10-01 1986-11-25 Biotek, Inc. Method of transdermal drug delivery
CA1272445A (en) * 1985-02-25 1990-08-07 Yie W. Chien Transdermal pharmaceutical absorption dosage unit and process of pharmaceutical administration
US4680172A (en) * 1985-03-05 1987-07-14 Ciba-Geigy Corporation Devices and methods for treating memory impairment

Also Published As

Publication number Publication date
GR3018010T3 (en) 1996-02-29
NZ223088A (en) 1991-01-29
CN87108380A (zh) 1988-08-24
EP0275716A1 (en) 1988-07-27
CA1313623C (en) 1993-02-16
DE3751447T2 (de) 1996-02-22
CN1021196C (zh) 1993-06-16
IE69752B1 (en) 1996-10-02
WO1989005663A1 (en) 1989-06-29
ATE126068T1 (de) 1995-08-15
DE3751447D1 (de) 1995-09-14
IE873541L (en) 1988-06-29
AU1242388A (en) 1989-07-19
EP0275716B1 (en) 1995-08-09

Similar Documents

Publication Publication Date Title
NZ223088A (en) Transdermal estrogen/progestin dosage unit
DE68926122D1 (de) Transdermale estrogen/progestin-dosiereinheit und system.
AU635182B2 (en) Transdermal absorption dosage unit for estradiol and other estrogenic steroids and process for administration
FI890995A0 (fi) Menetelmä narkoottista morfinaanianalgeettia tai -antagonistia sisältävän transdermaalisen, farmaseuttisen polymeerimatriksiannosteluyksikön valmistamiseksi
KR960703545A (ko) 테스토스테론의 공급을 위한 피부패치 및 방법(skin patches and methods for providing testosterone)
DE69506007D1 (de) Transdermales system zur gleichzeitigen verabreichung von mehreren wirkstoffen
NO895167D0 (no) Fremgangsmaate for behandling av tannrotsykdom ved vedvarende avgivelse av et farmasoeytisk middel til crevikularlommen, stoffblanding for dette og apparat for administrering derav.
HU906356D0 (en) Plaster containing oestrogenic active agents, and process for the preparation of such plasters
ES2043025T3 (es) Un procedimiento para preparar una composicion farmaceutica que contiene acido 3-(aminopropil)metil-fosfinico como agente terapeutico.
RU97112182A (ru) Трансдермальная система для одновременной дачи нескольких активных начал
GB2356812A (en) Segmented trans-dermal patches
AR003979A1 (es) Administracion transdermica de vorozol.
AU6229086A (en) Novel transdermal anti-anginal pharmaceutical dosage unit and process for its administration
Garren et al. Effects of thyroid hormone and propylthiouracil on eruption rate of upper incisor teeth in rats
EP1283706A1 (en) Dosage of transdermal delivery systems
KR900700142A (ko) 에스트로겐/프로게스틴 경피 투여 단위, 시스템 및 방법
DE69711075D1 (de) Transdermales arzneistoffverabreichungssystem zur behandlung von herzerkrankungen
RU94020918A (ru) Способ лечения опсоменореи
CA2261655A1 (en) Transdermal therapeutical approach involving a combination of active substances containing oestriol

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 275716

Country of ref document: ES